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Sunitinib has been registered for the treatment of advanced renal cell cancer (RCC). As patient inclusion was highly selective in
previous studies, experience with sunitinib in general oncological practice remains to be reported. We determined the efficacy and
safety of sunitinib in patients with advanced RCC included in an expanded access programme. ECOG performance status 41,
histology other than clear cell and presence of brain metastases were no exclusion criteria. Eighty-two patients were treated: 23%
reached a partial response, 50% had stable disease, 20% progressed and six patients were not evaluable. Median progression-free
survival (PFS) was 9 months and median overall survival (OS) was 15 months. Importantly, 47 patients (57%) needed a dose
reduction, 35 (43%) because of treatment-related adverse events, 10 (12%) because of continuous dosing, and two because of both.
Stomatitis, fatigue, hand–foot syndrome and a combination of grade 1–2 adverse events were the most frequent reasons for dose
reduction. In 40 patients (49%), there was severe toxicity, defined as dose reduction or permanent discontinuation, which was highly
correlated with low body surface area, high age and female gender. On the basis of age and gender, a model was developed that
could predict the probability of severe toxicity.
British Journal of Cancer (2008) 99, 259–265. doi:10.1038/sj.bjc.6604456 www.bjcancer.com
Published online 1 July 2008
& 2008 Cancer Research UK
Keywords: renal cell cancer; sunitinib; toxicity; dose reduction; non-clear cell histology
                                                 
Advanced renal cell cancer (RCC) has been recognised as a
chemoresistant disease. The only treatment available has been
cytokine-based therapy. Increasing knowledge of the underlying
biology of RCC, and more specifically, the clear cell subtype, has
recently changed the treatment options. Clear cell carcinomas,
which account for 75% of all RCC subtypes, appear to contain an
inactivated von Hippel–Lindau (VHL) tumour suppressor gene in
at least 60% of these tumours (Brugarolas, 2007). von Hippel–
Lindau gene alterations lead to elevated protein levels of hypoxia-
induced factor-a, which upregulates vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF) genes
and proteins (Brugarolas, 2007). The overexpression of these
growth factors results in blood vessel formation which may
account for the high vascular density of these tumours. Conse-
quently, tumour angiogenesis has become an interesting
therapeutic target in patients with metastatic RCC (mRCC).
Antiangiogenic agents, such as bevacizumab (Escudier et al,
2007b), sorafenib (BAY 43–9006) (Escudier et al, 2007a) and
sunitinib (SU011248) (Motzer et al, 2007) have demonstrated
significant antitumour activity in advanced RCC preferentially of
the clear cell type excluding patients with poor prognosis. In a
phase III clinical trial in mRCC, bevacizumab, a neutralising
antibody against VEGF, in combination with interferon-a pro-
longed progression-free survival (PFS) with 4.8 months as
compared to interferon-a alone (Escudier et al, 2007b). Sunitinib
and sorafenib are oral tyrosine kinase inhibitors of the VEGF and
PDGF receptors. In comparison with placebo, sorafenib prolonged
PFS in cytokine-pretreated mRCC with almost 3 months (Escudier
et al, 2007a). Sunitinib demonstrated a significantly prolonged PFS
(11 vs 5 months) as well as a higher objective response rate than
treatment with interferon-a (31 vs 6%) (Motzer et al, 2007).
Temsirolimus, an inhibitor of mammalian target of rapamycin
(mTOR) kinase, has demonstrated to improve the overall survival
(OS) in RCC patients with unselected cancer histology and poor
prognosis in comparison with interferon-a (11 months vs 7 and 8
months for, respectively, single-agent temsirolimus vs single-agent
interferon-a and the combination) (Hudes et al, 2007).
In the pivotal trials on sunitinib, patients had to fulfil
prespecified criteria. Eastern Cooperative Oncology Group (ECOG)
performance status 41, brain metastases, uncontrolled hyperten-
sion or clinically significant cardiovascular events or disease
during the preceding 12 months were exclusion criteria (Motzer
et al, 2006a,b, 2007). In addition, only patients with clear cell
histology were allowed for entry in two out of the three previous
studies (Motzer et al, 2006b, 2007). Nowadays, sunitinib can be
prescribed widely to patients with advanced RCC, but the
experience with this drug in an unselected patient population that
does not meet the above-described criteria has yet to be revealed.
Here, we report on a first experience with sunitinib treatment in a Revised 7 May 2008; accepted 9 May 2008; published online 1 July 2008
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slarge advanced-stage RCC patient population reflecting general
oncological practice and show that clinical benefit is comparable to
that observed in the earlier phase II/III trials. An unexpectedly
high number of patients, however, required dose reductions to
maintain an acceptable quality of life.
PATIENTS AND METHODS
Patient population
From December 2005 to September 2006, patients with histologi-
cally confirmed advanced RCC were enrolled in a global expanded
access programme (EAP) for treatment with sunitinib. Results are
reported for patients treated in two centres in Amsterdam (VU
University medical center and the Netherlands Cancer Institute).
Until May 2006, patients were included only after cytokine-based
therapy had failed and, thereafter, the drug was also available first-
line. Inclusion criteria were as follows: age 18 years of age or older,
adequate organ function (total serum bilirubin p2 upper limit
of normal (ULN), serum transaminases o5 ULN, serum
creatinine p2 ULN, absolute neutrophil count X1 10
9l
 1,
platelets X75 10
9l
 1, haemoglobin X5.0mmoll
 1) and resolu-
tion of all toxic effects of prior systemic therapy, radiotherapy or
surgical procedure according to National Cancer Institute-
Common Toxicity Criteria (NCI-CTC) version 3.0 grade p1.
Before entry into the programme, each participant had to sign an
institutional review board-approved protocol-specific informed
consent in accordance with the national and institutional guide-
lines, which strictly adhere to the principles of the Declaration of
Helsinki and its subsequent amendments.
Exclusion criteria were as follows: pregnancy or breast feeding,
concurrent treatment in another therapeutic trial, previous treat-
ment with sunitinib, congestive heart failure, myocardial infarction
or coronary artery bypass graft in the previous 6 months, ongoing
severe or unstable angina, any unstable arrhythmia requiring
medication or another severe acute or chronic medical or
psychiatric condition or laboratory abnormality that would make
the patient inappropriate for entry in this EAP.
Treatment, efficacy and adverse events
Sunitinib was administered orally at a dose of 50mg daily,
consisting of 4 weeks of treatment followed by a 2-week rest period
in cycles of 6 weeks. A dose reduction of sunitinib (to 37.5 or
25mg) was allowed depending on the type and severity of adverse
events. If patients had symptoms of progressive disease (PD)
during the rest period, there was the possibility for continuous
dosing of sunitinib at 37.5mg per day.
Patients underwent physical examination on day 1 of every
cycle. Complete blood cell count and serum chemistry tests were
carried out on day 1 and 28 of every treatment cycle. Complete
blood cell count was also performed on day 14 of the first cycle.
Electrocardiography was performed at baseline and on day 28 of
the first treatment cycle. Haematological and non-haematological
toxic effects were graded according to NCI-CTC version 3.0.
Toxicity evaluation was conducted on day 1, 14 and 28 of the first
treatment cycle and on day 1 and 28 of each treatment cycle
thereafter. If grade 3 haematological toxicity was recorded, the
treatment was withheld until the recovery grade p2 or blood
counts had returned to baseline after which sunitinib was resumed
at the same dose level. In case of grade 4 haematological toxicity
and grade 3 or 4 non-haematological toxicity, treatment was
delayed until side effects had recovered to grade p2 or grade 1,
respectively, or had returned to baseline after which the dose was
reduced by one level at the discretion of the treating physician. In
the case of grade 4 non-haematological toxicity, treatment was
discontinued.
Computed tomography (CT) or magnetic resonance imaging
(MRI) was performed at baseline and every two to three cycles
of treatment to assess clinical response according to
Response Evaluation Criteria in Solid Tumours (RECIST)
(Therasse et al, 2000).
Data analysis
Specific case report forms were used for data entry. For response
evaluation and toxicity, the cutoff date for data analysis was
1 March, 2007. For survival analysis, data collection was closed on
1 September, 2007. Patients were classified according to two
prognostic classification systems for mRCC: (1) the Memorial
Sloan–Kettering Cancer Center (MSKCC) prognostic criteria
(based on five risk factors: low Karnofsky performance status
(o80%), high lactate dehydrogenase (LDH, 41.5 times the ULN),
low serum haemoglobin, high-corrected serum calcium (410mg
per 100ml) and time from initial diagnosis to treatment of less
than 1 year) (Motzer et al, 2002) and (2) the prognostic criteria for
VEGF-targeted therapy according to Choueiri et al (2007) (based
on the following 5 risk factors: time from diagnosis to treatment
o2 years, baseline platelet count 4300 10
9l
 1, baseline
neutrophil count 44.5 10
9l
 1, baseline corrected calcium
o8.5mg per 100ml or 410mg per 100ml and initial ECOG
performance status 40).
Efficacy parameters were best response, time-to-treatment
failure (TTF), PFS and OS. The TTF was defined as the time
between the first day of treatment and the date of the first event
considered as failure of treatment. Such events could be disease
progression, early discontinuation (owing to unacceptable toxicity,
patient’s request and lost to follow-up) or death. The PFS was the
time between the first day of sunitinib and the date of PD on CT or
MRI, clear clinical evidence of PD or death owing to PD within 12
weeks after the last response evaluation. If a patient had not
progressed, PFS was censored at the time of the last follow-up. If
the PD date was unknown or a patient died owing to PD later than
12 weeks after the last response evaluation, PFS was censored at
the last adequate tumour assessment. Overall survival was the time
between the first day of treatment and the date of death or the date
at which patients were last known to be alive. Progression-free
survival and OS were calculated with the Kaplan–Meier method.
Severe toxicity was defined as dose reduction or permanent
discontinuation of sunitinib because of treatment-related adverse
events.
The following clinical characteristics were analysed for a
possible relation with severe toxicity: gender, age, body surface
area (BSA), ECOG performance status, tumour type, presence of
primary tumour, time of diagnosis to treatment, prior cytokine
based-therapy, previous radiation therapy, number of tumour
sites, liver metastases, MSKCC risk groups, Chouieri risk groups
and baseline biochemical parameters. Baseline biochemical
parameters (haemoglobin, LDH, albumin, creatinine, alkaline
phosphatase and corrected calcium) were all quantified as a factor
of the ULN. Statistical analysis was carried out using SPSS software
(SPSS for Windows 15.0, SPSS, Inc., Chicago, IL, USA). Univariate
logistic regression was performed to explore associations between
the separate clinical characteristics and severe toxicity. Thereafter,
the variables with a significance of Po0.05 were used for
multivariate logistic regression analysis.
RESULTS
Patients and treatment
Eighty-two patients with advanced RCC were registered in the
EAP. Patient characteristics are depicted in Table 1. Fourteen
patients had non-clear cell histology, 17 patients had a
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sperformance status of ECOG 41, 16 patients had a concurrent
primary tumour in situ and five patients had concurrent brain
metastases. All patients received sunitinib for a period of at least 1
week. At the time of the analysis, 18 patients were still on study
and 64 had discontinued sunitinib. Reasons for termination were
PD (n¼44), adverse events either related to treatment or disease
(n¼14), early death (n¼3), nephrectomy after downsizing of the
primary tumour (n¼2) and radiofrequency ablation of liver
metastases (n¼1).
Efficacy
With respect to best response, 19 (23%) patients achieved a partial
response (PR) (15 confirmed and four non-confirmed), 41 (50%)
patients had stable disease (SD) and 16 (20%) patients had PD. Six
patients could not be evaluated, five as a result of early termination
and one patient because of bone metastases only. Impressive
responses were observed in the 16 primary tumours (Van der
Veldt et al, 2008) and six of them achieved a PR. Ten out of 14
patients with non-clear cell histology and two out of five patients
with brain metastases had SD. No objective responses
were observed in these subgroups. Seven patients developed
symptomatic brain metastases as first or only sign of PD
(Helgason et al, 2008).
Excluding the three patients with nephrectomy and radio-
frequency ablation, the median TTF in 61 patients who discon-
tinued treatment with sunitinib, was 3.6 months (range: 0.3–18.4
months). The median PFS (n¼77) was 9.3 months (range:
0.5–18.3 months; Table 2). The patient with bone metastases only
was included in PFS and had clinical benefit lasting 48 months.
PFS was censored for the patient with radiofrequency ablation. The
median PFS in the 14 patients with non-clear cell histology was 3.2
months (range: 1.2–17.0 months). The median OS for the total
patient population was 15.0 months (range: 0.5–19.4 months;
Table 2).
Additional analyses were carried out with respect to individual
patient characteristics and the course of the disease. Both the
MSKCC criteria (Motzer et al, 2002) and the criteria according to
Choueiri et al (2007) correctly predicted the PFS (P¼0.001 and
P¼0.007, respectively) as well as the OS (Po0.001 and P¼0.002,
respectively; Table 2 and Figure 1). The predictive value of the
number of disease sites was rather low, but for OS, the number of
disease sites still had prognostic value (P¼0.039).
Safety and dose reductions
The most frequent non-haematological grade 1–2 adverse events
were stomatitis, nausea, diarrhoea, vomiting, fatigue, hand–foot
syndrome and taste alteration (Table 3). Grade 3 adverse events
most frequently occurring were hand–foot syndrome (11%),
stomatitis (9%), diarrhoea (7%), fatigue (6%) and hypertension
(6%). Detailed information on three patients with reversible
cognitive disorders grade 2–3 has been published elsewhere
(Van der Veldt et al, 2007). Thrombocytopenia, leucocytopenia
and neutropenia were the most frequently reported haematological
adverse events (Table 4). The frequency of grade 3 haematological
adverse events was also low, being lymphopenia (9%), thrombo-
cytopenia (7%), neutropenia (7%), leucocytopenia (5%) and
anaemia (1%). No grade 4 adverse events were observed.
In 40 (49%) patients, there was severe toxicity requiring dose
reduction in 37 patients (median time to dose reduction 1.4
months, range: 0.2–12.4 months) and permanent discontinuation
in three patients (for all three patients within 0.5 month; Table 5).
Dose reduction in at least 6 out of 37 patients was not sufficient to
alleviate symptoms, because of which sunitinib had to be
discontinued. Stomatitis grade 3 was the most frequently reported
reason for dose reduction, followed by fatigue, hand–foot
syndrome and the combination of several grade 1–2 adverse
events. In addition, 10 (12%) patients needed continuous dosing
because of PD or recurrence of disease-related symptoms during
the 2-week rest period (median time to continuous dosing
3.1 months, range: 1.1–11.8 months). Two patients had dose
Table 1 Patient characteristics
Total n¼82
Variable n (%)
Sex
Male 55 (67)
Female 27 (33)
Median age, years (range) 60 (25–84)
ECOG performance status
0 33 (40)
1 29 (35)
2 12 (15)
3 5 (6)
Unknown 3 (4)
Tumour type
Clear cell 68 (83)
Other 14 (17)
Previous nephrectomy 66 (80)
Prior treatment
None 26 (32)
Cytokine based-therapy 53 (65)
Antiangiogenic therapy 5 (6)
Previous radiation therapy 25 (30)
Number of disease sites
1 11 (13)
2 31 (38)
X3 40 (49)
Sites of disease
Lung 66 (80)
Lymph nodes 43 (52)
Bone 26 (32)
Liver 22 (27)
Local recurrence 10 (12)
Brain 5 (6)
MSKCC risk groups
a
0 (favourable) 20 (24)
1–2 (intermediate) 41 (50)
X3 (poor) 17 (21)
Unknown 4 (5)
Chouieri risk groups
b
1 (0 or 1 adverse prognostic factor) 16 (20)
2 (2 adverse prognostic factors) 18 (22)
3( 42 adverse prognostic factors) 48 (59)
ECOG¼Eastern Cooperative Oncology Group; LDH¼lactate dehydrogenase;
MSKCC¼Memorial Sloan–Kettering Cancer Center; VEGF¼vascular endothelial
growth factor.
aRisk groups according to MSKCC prognostic criteria (based on the
five risk factors: low Karnofsky performance status (o80%), high LDH (41.5 times
the upper limit of normal), low serum haemoglobin, high-corrected serum calcium
(410mg per 100ml) and time from initial diagnosis to treatment of less than 1 year;
Motzer et al, 2002).
bPrognostic risk groups for VEGF-targeted therapy according to
Chouieri et al (2007) (based on the five risk factors: time from diagnosis to treatment
o2 years, baseline platelet count 4300 10
9l
 1, baseline neutrophil count
44.5 10
9l
 1, baseline corrected calcium o8.5mg per 100ml or 410mg per
100ml and initial ECOG performance status 40).
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sreduction because of both toxicity and continuous dosing (time to
dose reduction 1.4 and 4.2 months).
Female gender, high age, low BSA and to a lesser extent also high
LDH were significantly related with severe toxicity (univariate
logistic regression; P¼0.006, P¼0.006, P¼0.005 and P¼0.035,
respectively). There was no significant relation between severe
toxicity and the separate prognostic risk groups according to the
MSKCC criteria (Motzer et al, 2002) as well as the criteria of
Choueiri et al (2007). In multivariate logistic regression of gender,
age, BSA and LDH, the latter two variables appeared to be of no
additional significance in the prediction of severe toxicity. In
multivariate logistic regression, gender and age had a significant
effect (P¼0.018 and P¼0.024, respectively) and the combination
of these two variables was highly predictive for severe toxicity
(P¼0.001). On the basis of gender and age, a model was developed
to predict the probability of severe toxicity in male patients and
female patients (Figure 2).
DISCUSSION
We here describe the efficacy and safety of sunitinib treatment in
an unselected mRCC patient population as can be found in general
oncological practice. In our mRCC patients, the SD rate (50%)
resembled that observed in the large phase III clinical trial in
which sunitinib was compared with interferon-a, but the PR rate
was slightly less (23 vs 31%; Motzer et al, 2007). The PR rate in
patients with clear cell histology (28%), however, was similar to
that in the phase III study in patients with clear cell mRCC only
(Motzer et al, 2007). The MSKCC risk groups (Motzer et al, 2002)
appropriately predicted PFS and OS in this patient population,
which indicates that the Motzer prognostic factors model is still
valid to predict survival in mRCC in the sunitinib era. The
prognostic criteria of Choueiri et al (2007) designed for patients
with clear cell histology receiving VEGF-targeted therapy, however,
did not discriminate a difference in OS between risk groups 1 and
2 in our patient population. An explanation may be that we have
treated a large number of cytokine-pretreated patients (65%) as
well as patients with non-clear cell histology (17%).
In the non-clear cell histology patient population, 10 out of 14
patients had SD, whereas no PR was observed. Recently, Choueiri
et al (2008) have reported their experience with sunitinib and
sorafenib in patients with non-clear cell histology. During either
sunitinib or sorafenib treatment, 5 out of 53 patients with non-
clear cell histology, either papillary or chromophobe tumours,
reached a PR, whereas 36 patients had SD of more than 3 months.
Table 2 Best tumour response, progression-free survival and overall survival
Best tumour response
PR SD PD NE Median PFS
a Median OS
a
Variable n (%) n (%) n (%) n (%) Months (range) Months (range)
All patients 19 (23) 41 (50) 16 (20) 6 (7) 9.3 (0.5–18.3) 15.0 (0.5–19.4)
Histology P¼0.528 P¼0.105
Clear cell histology 19 (23) 31 (38) 12 (15) 6 (7) 9.3 (0.5–18.3) 15.0 (0.5–19.4)
Non-clear cell histology 0 (0) 10 (12) 4 (5) 0 (0) 3.2 (1.2–17.0) 6.5 (1.4–18.4)
ECOG performance status P¼0.397 P¼0.049
ECOG p1 14 (17) 34 (41) 12 (15) 2 (2) 9.4 (1.2–17.0) NR (1.8–18.9)
ECOG 41 5 (6) 6 (7) 3 (4) 3 (4) 8.9 (0.5–18.3) 9.7 (0.5–19.4)
Unknown 0 (0) 1 (1) 1 (1) 1 (1) 1.2 (1.2–13.2) 2.2 (0.5–13.2)
MSKCC risk groups
b P¼0.001 Po0.001
0 (favourable) 6 (7) 11 (13) 2 (2) 1 (1) 11.6 (1.1–17.0) NR (2.0–18.9)
1–2 (intermediate) 9 (11) 23 (28) 7 (9) 2 (2) 9.6 (1.2–18.3) 15.4 (4.3–19.4)
X3 (poor) 2 (2) 6 (7) 7 (9) 2 (2) 2.6 (0.5–17.0) 3.6 (0.5–16.5)
Unknown 2 (2) 1 (1) 0 (0) 1 (1) 9.7 (9.3–13.2) 15.0 (0.5–15.0)
Choueiri risk groups
c P¼0.007 P¼0.002
1 (0 or 1 adverse prognostic factor) 3 (4) 8 (10) 4 (5) 1 (1) 12.2 (1.2–17.0) NR (3.6–18.9)
2 (2 adverse prognostic factors) 8 (10) 8 (10) 1 (1) 1 (1) 12.2 (2.1–18.3) NR (4.7–19.4)
3( 42 adverse prognostic factors) 8 (10) 25 (30) 11 (13) 4 (5) 7.0 (0.5–16.1) 10.8 (0.5–17.7)
Number of disease sites P¼0.096 P¼0.039
1 1 (1) 7 (9) 2 (2) 1 (1) NR (1.2–17.0) NR (3.6–17.2)
2 11 (9) 13 (16) 5 (6) 2 (2) 9.7 (0.9–18.3) NR (1.5–19.4)
X3 7 (9) 21 (26) 9 (11) 3 (4) 8.4 (0.5–16.1) 11.0 (0.5–18.4)
Miscellaneous
Concurrent primary tumour 6 (7) 6 (7) 4 (5) 0 (0) 9.3 (0.9–16.1) 15.0 (1.4–17.7)
Concurrent brain metastases 0 (0) 2 (2) 2 (2) 1 (1) 3.0 (2.6–12.2) 7.5 (3.6–18.4)
Previous cytokine-based therapy 14 (17) 27 (33) 8 (10) 4 (5) 10.6 (1.2–18.3) NR (0.5–19.4)
Previous antiangiogenic therapy 1 (1) 1 (1) 2 (2) 1 (1) 2.6 (1.2–18.3) 4.6 (3.6–19.4)
ECOG¼Eastern Cooperative Oncology Group; LDH¼lactate dehydrogenase; MSKCC¼Memorial Sloan–Kettering Cancer Center; NE¼not evaluable; NR¼median not
reached; OS¼overall survival; PD¼progressive disease; PFS¼progression-free survival; PR¼partial response; SD¼stable disease; VEGF¼vascular endothelial growth factor.
aMedian PFS and OS were calculated with the Kaplan–Meier method.
bRisk groups according to MSKCC prognostic criteria (based on the five risk factors: low Karnofsky
performance status (o80%), high LDH (41.5 times the upper limit of normal), low serum haemoglobin, high-corrected serum calcium (410mg per 100ml) and time from
initial diagnosis to treatment of less than 1 year; Motzer et al, 2002).
cPrognostic risk groups for VEGF-targeted therapy according to Chouieri et al (2007) (based on the five risk
factors: time from diagnosis to treatment o2 years, baseline platelet count 4300 10
9l
 1, baseline neutrophil count 44.5 10
9l
 1, baseline corrected calcium o8.5mg per
100ml or 410mg per 100ml and initial ECOG performance status 40).
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sThe present data and the study of Choueiri et al (2008) indicate
that patients with non-clear cell histology may benefit from
sunitinib. Furthermore, patients with poor performance status
(ECOG 41) and brain metastases also experienced benefit from
sunitinib treatment in 65 and 40% of cases, respectively.
Treatment-related adverse events were mostly grade 1 or 2 and
only few grade 3 toxicities were observed. The incidence rates of
the most common grade 3 adverse events requiring dose
discontinuation and/or reduction, such as hand–foot syndrome,
stomatitis, diarrhoea, fatigue and hypertension were grossly
similar to the rates reported in previous trials (Demetri et al,
2006; Motzer et al, 2006a,b, 2007). In this patient population, we
observed a relatively lower incidence of thrombocytopenia and
leucocytopenia than that reported in the largest trial on sunitinib
so far (Motzer et al, 2007). Although thyroid function was not
measured consistently, only five patients experienced hypo-
thyroidism grade 1–2 (data not shown).
More than half of our patients needed a dose reduction of
sunitinib and 35 out of 82 patients (43%) because of treatment-
related adverse events. In comparison, only for 32% of the patients
treated with sunitinib in the large randomised phase III trial of
sunitinib vs IFN-a a dose reduction was reported, which might
partially be explained by a higher number of patients with ECOG
X1 in our population. The remarkably high number of dose
reductions, however, was not only based on grade 3 toxicities, but
also on the accumulation of a series of grade 1 and 2 adverse
events. These toxicities were palliated in every possible way.
Some adverse events, however, interfered excessively with daily
life, such as stomatitis and taste alteration requiring changes in
food habits, hand–foot syndrome limiting walking and the urgent
pattern of diarrhoea with risk for soiling. In this respect, the NCI-
CTC grading system is inadequate to express the impact of
particular toxicities of sunitinib for the well-being of the patient.
Our findings are indicative that the sunitinib dosing schedule is
not optimal for unselected mRCC patients and that a number of
patients are initially overtreated resulting in unnecessary adverse
events. On the other hand, patients who do not experience any
toxicity may be undertreated. Therefore, dosing on the basis of
BSA might be meaningful, as BSA was highly correlated with
severe toxicity. In the previous phase I study in patients with solid
tumours, the simulated intrapatient variability in drug plasma
levels between BSA-normalised and fixed dosing was comparable
on days 1 and 28 for both sunitinib and its major plasma
metabolite SU012622 (Faivre et al, 2006). It was concluded that no
or minimal improvement in variability could be expected from
calculating the dose on the basis of BSA. With respect to our data,
it should be reconsidered to administer initial doses on the basis of
BSA and taper off to tolerable doses if required, or increase the
dose if no toxicity is observed. Alternatively, population-based
sunitinibþSU012622 plasma levels could be of help to develop
better algorithms for optimal sunitinib dosing.
With the use of the fixed dosing regimen, we not only found a
highly significant correlation between severe sunitinib-related
toxicity and patient characteristics BSA, but also with female
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Figure 1 Kaplan–Meier curves for progression-free survival and overall survival of mRCC patients treated with sunitinib for risk groups 1 (y), 2 (—) and
3 (– –) according to the MSKCC criteria (Motzer et al, 2002) (A and C) and the criteria according to Choueiri et al (2007) (B and D).
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sgender and high age. We developed a model to predict the
probability of severe toxicity based on gender and age in which
BSA was not additive. Although the model requires external
validation, it might be helpful to closely monitor patients at risk to
develop invalidating adverse events on sunitinib given in the
currently proposed schedule. It can also be proposed to dose
patients on BSA and determine, whether female gender and high
age remain prognostic factors for severe toxicity. Any grade 3
toxicity was also significantly related to gender and BSA, but not to
age. The occurrence of any grade 3 adverse event was the reason
for dose reduction or discontinuation of sunitinib in 79% of these
patients.
Ten (12%) patients required continuous dosing at a lower dose
of 37.5mg daily owing to objective disease progression or
recurrence of disease-related symptoms in the 2-week period of
rest of the treatment cycle. Two phase II studies have demon-
strated that the safety of a continuous dosing schedule of 37.5mg
per day in patients with RCC and gastrointestinal stromal tumours
(GIST) was similar to that of the intermittent schedule (George
Table 3 Non-haematological adverse events
Non-haematological
adverse event
a
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%) All %
Stomatitis 34 (41) 17 (21) 7 (9) 71
Nausea 31 (38) 9 (11) 4 (5) 54
Diarrhoea 27 (33) 8 (10) 6 (7) 50
Hand-foot syndrome 16 (20) 9 (11) 9 (11) 41
Fatigue 12 (15) 14 (17) 5 (6) 38
Vomiting 22 (27) 5 (6) 0 (0) 33
Taste alteration 20 (24) 6 (7) 0 (0) 32
Hypertension 5 (6) 9 (11) 5 (6) 23
Anorexia 6 (7) 12 (15) 0 (0) 22
Headache 7 (9) 6 (7) 2 (2) 18
Yellow skin 12 (15) 0 (0) 0 (0) 15
Rash/desquamation 8 (10) 4 (5) 0 (0) 15
Fever 7 (9) 4 (5) 0 (0) 13
Heartburn 7 (9) 4 (5) 0 (0) 13
Pain extremity 7 (9) 2 (2) 0 (0) 13
Esophagitis 5 (6) 3 (4) 1 (1) 11
Gastric complaints 7 (9) 2 (2) 0 (0) 11
Myalgia 8 (10) 1 (1) 0 (0) 11
Periorbital oedema 9 (11) 0 (0) 0 (0) 11
Dizziness 7 (9) 1 (1) 0 (0) 10
Epistaxis 8 (10) 0 (0) 0 (0) 10
Oedema 3 (4) 2 (2) 1 (1) 7
Pain mouth 2 (2) 1 (1) 1 (1) 5
Muscle weakness 0 (0) 2 (2) 1 (1) 4
Cognitive disorder 0 (0) 2 (2) 1 (1) 4
Hyperthyroidism 0 (0) 0 (0) 1 (1) 1
Transient ischaemic attack 0 (0) 0 (0) 1 (1) 1
aAdverse events grade 1 and 2 occurring in at least 10% of patients and all grade 3
events.
Table 4 Haematological adverse events
Haematological
adverse event
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%) All %
Thrombocytopenia 27 (33) 7(9) 6 (7) 49
Leucocytopenia 17 (21) 16 (20) 4 (5) 45
Neutropenia 7 (9) 13 (16) 6 (7) 32
Lymphopenia 7 (9) 7 (9) 7 (9) 26
Anaemia 10 (12) 9 (11) 1 (1) 24
Table 5 Severe toxicity causing change of sunitinib dosing
Reasons for dose reduction n (¼37)
Non-haematological
Stomatitis grade 3 6
Fatigue grade 3 5
Hand-foot syndrome grade 2–3 5
Combination of several grade 1–2 toxicities 5
Diarrhoea grade 3 2
Cognitive disorder grade 2–3 2
Esophagitis grade 3 1
Headache grade 3 1
Hypertension grade 3 1
Pain mouth grade 3 1
Transient ischaemic attack grade 3 1
Haematological
Neutropenia grade 3 3
Thrombocytopenia grade 3 3
Leucocytopenia grade 3 1
Reasons for permanent discontinuation at once n (¼3)
Cognitive disorder grade 2 1
Hypertension grade 3 1
Stomatitis grade 2 1
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Figure 2 Probability of severe toxicity from sunitinib (50mg per day 4 weeks on and 2 weeks off) in patients with advanced RCC based on the following
model: Probability of severe toxicity in male patients¼exp ( 3.986þ0.059*age)/(exp ( 3.986þ0.059*age)þ1) Probability of severe toxicity in female
patients¼exp ( 2.750þ0.059*age)/(exp ( 2.750þ0.059*age)þ1) Grey lines represent confidence intervals.
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set al, 2007; Srinivas et al, 2007). In addition, preliminary results
suggest a comparable PFS and OS for the two dosing schedules
(Faivre et al, 2007), although the objective response rate appears to
be lower. In mRCC, the 4 weeks on and 2 weeks off schedule is the
most preferred as a direct relation between the exposure to
sunitinib (area under the plasma concentration-time curve), which
is the highest during the 4 weeks on 50mg per day, and a higher
probability of PR, longer time-to-tumour progression, longer OS
and greater decrease in tumour volume have been observed (Houk
et al, 2007).
In conclusion, sunitinib demonstrates clinical benefit in
unselected mRCC patients, including patients with non-clear cell
histology, brain metastases and an ECOG performance status 41.
The need for dose reduction owing to adverse events in this
unselected mRCC patient population is rather high. Gender, age
and BSA are highly predictive of severe toxicity. Attempts to
optimise the dosing schedule of sunitinib in unselected mRCC
patients are warranted.
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